-
When the University of Michigan Health System's chief risk officer arrived in 2001, he had already mapped out to institutional leaders an architecture for risk management and medical error disclosure that would dramatically change the system's liability expenses, as well as its approach to patient safety.
-
As medical scientists and engineers in the health care arena pursue advances in drugs and technologies, is now the time to think more critically about these new technologies and how to address future implications for say, the ramifications of genetic screening and designer babies?
-
Most physicians reported in a national survey that they would discuss end-of-life options with a terminally ill patient only when there were no more treatments to offer that patient not when the patient was still feeling well, according to a study published online in CANCER, a peer-reviewed journal of the American Cancer Society, in January.
-
Technological advances in medicine have the capability of helping health care providers to prolong life for patients faced with a terminal illness or injury.
-
-
-
Each clinical trial administrator and investigator needs to understand the motivations of all parties involved including his or her own before beginning a clinical trial contract negotiation process.
-
Oncologists and medical directors say that 38% of their patients could benefit from participation in clinical trials, but only about 5% actually enroll in an oncology study per month, according to a recent survey.
-
The University of Pittsburgh in Pittsburgh, PA, has developed a thorough, review process that serves as an educational opportunity, as well as a way to prevent clinical research problems.
-
Increasing numbers of research institutions have opened offices to provide oversight of investigator-initiated clinical trials, but they often lack the basic tools needed for this process.